Search Within

Lymphoma

Formats
  1. Meeting Abstract (1382)
  2. Journal Article (1055)
  3. Book Section (64)
  4. Review (64)
  5. Editorial (38)
  6. Research Letter (38)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2694)
  2. Department of Medicine (2694)
  3. Hematologic Malignancies, Division of (2694)
  4. Population Sciences Research Program (742)
  5. Survivorship Research (654)
  6. Executive Committee, Center for Hematologic Malignancies (391)

More Groups

People
  1. Andrew Zelenetz (781)
  2. Steven Horwitz (664)
  3. Maria Palomba (443)
  4. Ariela Noy (369)
  5. David Straus (360)
  6. Alison Moskowitz (355)

More People

Years
  1. 2025 (41)
  2. 2024 (141)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (875)
  2. Journal of Clinical Oncology (277)
  3. Hematological Oncology (110)
  4. British Journal of Haematology (81)
  5. Leukemia and Lymphoma (81)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (940)
  2. American Society of Clinical Oncology (293)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (174)
  5. John Wiley & Sons (96)
  6. Nature Publishing Group (93)

More Publishers

Results (2694)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluation of quality of biomarker data capture by peripheral sites in an international, cooperative study: Analysis of 104 cases from the T-cell project
    Meeting Abstract

    Pileri, S. A.; Bellei, M.; Vose, J. M.; Connors, J. M.; Foss, F. M.; Horwitz, S. M.; Montoto, S.; Polliack, A.; Zinzani, P. L.; Zucca, E.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • Impact of the conditioning chemotherapy on outcomes in adoptive T cell therapy: Results from a phase I clinical trial of autologous CD19-targeted T cells for patients with relapsed CLL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Stefanski, J.; He, Q.; Taylor, C.; Olszewska, M.; Wasielewska, T.; Bartido, S.; Davila, M. L.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • Evaluation of dual tracer (FLT and FDG) PET imaging as part of risk-adapted therapy for patients with advanced stage diffuse large B cell lymphoma (DLBCL)
    Meeting Abstract

    Moskowitz, C. H.; Schoder, H.; Hamlin, P.; Maragulia, J. C.; Walkley, J.; Zelenetz, A. D.
    Blood (2012)

    Fulltext@MSK | Save
  • Semi-quantitative evaluation of pre-transplant FDG-PET in relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A.; Maragulia, J. C.; Kumar, A.; Moskowitz, C. H.
    Blood (2012)

    Fulltext@MSK | Save
  • Pralatrexate in relapsed/refractory HTLV-1 associated adult T-cell lymphoma/leukemia: A New York City multi-institutional experience
    Meeting Abstract

    Lunning, M. A.; Gonsky, J.; Ruan, J.; Phillips, A. A.; Pulitzer, M.; Moskowitz, A.; Querfeld, C.; Myskowski, P. L.; Noy, A.; Horwitz, S. M.
    Blood (2012)

    Fulltext@MSK | Save
  • CD30 is a potential therapeutic target in patients with HTLV-1 associated adult T-cell leukemia/lymphoma presenting outside of Japan
    Meeting Abstract

    Lunning, M. A.; Chiu, A.; Feldstein, J. T.; Maragulia, J. C.; Moskowitz, A.; Matasar, M. J.; Straus, D. J.; Noy, A.; Myskowski, P. L.; Zelenetz, A. D.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • Prioritizing content in continuing hematologic oncology education: A survey of 51 clinical investigators
    Meeting Abstract

    Love, N.; Horwitz, S. M.; Lonial, S.; Palumbo, A.; Smith, M. R.; Hussein, A. M.; Ziel, K.
    Blood (2012)

    Fulltext@MSK | Save
  • Clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides: A single center experience from Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Li, J. Y.; Pulitzer, M.; Myskowski, P. L.; Dusza, S.; Horwitz, S. M.; Moskowitz, A.; Querfeld, C.
    Blood (2012)

    Fulltext@MSK | Save
  • Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression
    Meeting Abstract

    Krathen, M.; Sundram, U.; Bashey, S.; Sutherland, K.; Salva, K.; Wood, G. S.; Advani, R. H.; Hoppe, R. T.; Reddy, S.; Armstrong, R.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: Interim results
    Meeting Abstract

    Jacobsen, E. D.; Advani, R. H.; Oki, Y.; Sharman, J.; Horwitz, S. M.; Forero-Torres, A.; O'Connor, O. A.; Shustov, A. R.; Siddiqi, T.; Grove, L. E.; more...
    Blood (2012)

    Fulltext@MSK | Save